# Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers

Page: https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-symptom-duration-impact-on-bimekizumab-efficacy-and-therapeutic-switching-drivers
Text version: https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-symptom-duration-impact-on-bimekizumab-efficacy-and-therapeutic-switching-drivers.md
Podcast: [The IMID Forum](https://stenobird.com/podcast/the-imid-forum-981476)
Published: 2026-03-19T11:00:28+00:00
Episode link: https://soundcloud.com/imidforum/discussing-axspa-symptom
Audio file: https://feeds.soundcloud.com/stream/2286096554-imidforum-discussing-axspa-symptom.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-axspa-symptom-duration-impact-on-bimekizumab-efficacy-and-therapeutic-switching-drivers
Duration seconds: 2009

## Resource

Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-axspa-symptom-duration-impact-on-bimekizumab-efficacy-and-therapeutic-switching-drivers/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-axspa-symptom-duration-impact-on-bimekizumab-efficacy-and-therapeutic-switching-drivers.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.